title: Antimicrobial and antimotility agent use in persons with shiga toxin-producing Escherichia coli O157 infection in FoodNet Sites.
abstract: Antimicrobial and antimotility agents are not recommended for the treatment of Shiga toxin-producing Escherichia coli O157 infection. In our study, many persons with Shiga toxin-producing E. coli O157 infection took antimicrobial (62%) and antimotility agents (32%); 43 (29%) of 146 reported commencing antimicrobial treatment after laboratory confirmation. Efforts are needed to promote practice guidelines.
authors.affiliation: Emory University, GA, USA.
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Nelson
authors.forename: Patricia M
authors.initials: PM
authors.lastname: Griffin
authors.forename: Timothy F
authors.initials: TF
authors.lastname: Jones
authors.forename: Kirk E
authors.initials: KE
authors.lastname: Smith
authors.forename: Elaine
authors.initials: E
authors.lastname: Scallan
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D004157:Diphenoxylate / Q000009:adverse effects / Q000627:therapeutic use; D004927:Escherichia coli Infections / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D019453:Escherichia coli O157 / Q000187:drug effects*; D006463:Hemolytic-Uremic Syndrome / Q000453:epidemiology / Q000209:etiology* / Q000382:microbiology; D006801:Humans; D008139:Loperamide / Q000009:adverse effects / Q000627:therapeutic use; D010276:Parasympatholytics / Q000009:adverse effects* / Q000627:therapeutic use; D011159:Population Surveillance / Q000379:methods; D010818:Practice Patterns, Physicians'; D022603:Shiga Toxins / Q000096:biosynthesis*; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D010276:Parasympatholytics; D022603:Shiga Toxins; D008139:Loperamide; D004157:Diphenoxylate